Eric Lawitz, MD, is the medical director of the Texas Liver Institute and a clinical professor of medicine at the University of Texas Health San Antonio.
Insights from Long-Term ASSURE Data for Seladelpar
Trivedi and Lawitz review long-term data from the phase 3 open-label ASSURE study and explain what they add to our understanding of seladelpar for PBC.
Read More
What Sets Seladelpar Apart From Other PBC Therapies
Trivedi and Lawitz discuss what sets seladelpar apart from other PBC therapies in the rapidly evolving treatment landscape.
The Clinical Impact of Seladelpar in PBC Care
Trivedi and Lawitz discuss the clinical impact of having seladelpar as a second-line treatment option for patients with PBC.
Understanding Seladelpar as a Second-Line Treatment for PBC
Trivedi and Lawitz discuss seladelpar’s mechanism of action and its use as a second-line therapy in PBC.